A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, is safe and tolerable in the treatment of advanced malignancies.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Performance status 0-1
• Adequate organ function
• Cohort M1, 2 and C1: Measurable disease
• Cohort M1, M2 and C1: Subjects must have histologic or cytologic confirmation of an advanced (metastatic and/or unresectable) malignant solid tumor
• Cohort C2: Documented refractory or relapsed multiple myeloma
• Subjects must be refractory to or have relapsed after standard therapies, or have no known effective treatment

Exclusion Criteria:

• Cohort M1, M2, and C1: Untreated or active central nervous system (CNS) or leptomeningeal metastases
• Cohort M1, M2, and C1: Subjects with hepatocellular carcinoma (HCC)
• Cohort C2: Subjects with solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia

Other protocol defined inclusion/exclusion criteria could apply